In 2007, Stephen and Erin Chance created CURE Childhood Cancer’s first “Named fund.” Their son, Patrick, had been diagnosed with Stage Iv Neuroblastoma at three years old. After realizing the dire need for funding for pediatric cancer research, the Chances created Press On: The Patrick R. Chance fund for Neuroblastoma Research to combine their fundraising efforts with the shared vision, experience, and success of CURE Childhood Cancer.
The Press On fund mission changed in an ironically positive direction in 2009 when Tara and Turner Simkins, dear friends of the Chances and early supporters of Press On, joined forces with the Chances as a result of their son, Brennan’s, diagnosis with AMl on the eve of his seventh birthday. During Brennan’s bone marrow transplant, and after Patrick had been off therapy for only three short months, Patrick’s cancer returned. Then, just three months later, Brennan relapsed. Both boys and their families and supporters are fighting to find a cure.
The Chances and Simkins have shared a friendship practically their entire lives. Now they also share the mission of the Press On fund. The brutal irony of their sons’ battles with cancer underscores their firm belief that their continuing experience “in the trenches” with their boys offers a providential opportunity to help raise money which can be targeted directly to therapies and trials which can make a difference now. from this perspective, their lives will be always changed for the better, relying on the strength of true friendship and faith to Press On through any circumstances for a CURE.
As a result of the generous support of family, friends, and a community of supporters, The Press On fund has directed several hundreds of thousands of dollars to promising research for neuroblastoma, specifically Dr. Donald Durden’s research of Pl-3 Kinase Inhibitor and Targeted Therapies for neuroblastoma conducted at Emory University and Children’s Healthcare of Atlanta. Press On has also directed $20,000 to Memorial Sloan Kettering Cancer Center to support a team of dedicated neuroblastoma researchers investigating antibody therapies.